AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

In the company’s first insider transaction in nearly a year, Hirawat bought approximately $100,000 worth of BMY stock on Nov.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...

More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control scheme included in the Inflation Reduction Act. President Biden is set to lay out his ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bristol Myers is expected to post earnings of $1.51 per ...

Bristol-Myers Squibb Leads Biopharma Recovery With ... citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

BMY) have crossed above the average analyst 12-month target price of $53.55, changing hands for $55.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways ...